Literature DB >> 23759508

In vivo cardiovascular pharmacology of 2',3'-cAMP, 2'-AMP, and 3'-AMP in the rat.

Edwin K Jackson1, Zaichuan Mi.   

Abstract

UNLABELLED: The naturally occurring purine 2',3'-cAMP is metabolized in vitro to 2'-AMP and 3'-AMP, which are subsequently metabolized to adenosine. Whether in vivo 2',3'-cAMP, 2'-AMP, or 3'-AMP are rapidly converted to adenosine and exert rapid effects via adenosine receptors is unknown. To address this question, we compared the cardiovascular and renal effects of 2',3'-cAMP, 2'-AMP, 3'-AMP, 3',5'-cAMP, 5'-AMP, and adenosine in vivo in the rat. Purines were infused intravenously while monitoring mean arterial blood pressure (MABP), heart rate (HR), cardiac output, and renal and mesenteric blood flows. Total peripheral (TPR), renal vascular (RVR), and mesenteric vascular (MVR) resistances were calculated. Urine was collected for determination of urine excretion rate [urine volume (UV)]. When sufficient urine was available, the sodium excretion rate (Na(+)ER) and glomerular filtration rate (GFR) were determined. 2',3'-cAMP, 2'-AMP, and 3'-AMP dose-dependently and profoundly reduced MABP, HR, TPR, and MVR with efficacy and potency similar to adenosine and 5'-AMP. These effects of 2',3'-cAMP, 2'-AMP, and 3'-AMP were attenuated by blockade of adenosine receptors with 1,3-dipropyl-8-(p-sulfophenyl)xanthine. 2',3'-cAMP, 2'-AMP, 3'-AMP, adenosine, and 5'-AMP variably affected RVR, but profoundly (nearly 100%) decreased UV at higher doses. GFR and Na(+)ER could be measured at the lower doses and were suppressed by 2',3'-cAMP, 2'-AMP, and 3'-AMP, but not by adenosine or 5'-AMP. 2',3'-cAMP increased urinary excretion rates of 2'-AMP, 3'-AMP, and adenosine. 3',5'-cAMP exerted no adverse hemodynamic effects yet increased urinary adenosine as efficiently as 2',3'-cAMP.
CONCLUSIONS: In vivo 2',3'-cAMP is rapidly converted to adenosine. Because both cAMPs increase adenosine in the urinary compartment, these agents may provide unique therapeutic opportunities.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23759508      PMCID: PMC3716313          DOI: 10.1124/jpet.113.205757

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  28 in total

1.  Extracellular 2',3'-cAMP and 3',5'-cAMP stimulate proliferation of preglomerular vascular endothelial cells and renal epithelial cells.

Authors:  Edwin K Jackson; Delbert G Gillespie
Journal:  Am J Physiol Renal Physiol       Date:  2012-07-11

2.  Endogenous adenosine restrains renin release in conscious rats.

Authors:  C J Kuan; J N Wells; E K Jackson
Journal:  Circ Res       Date:  1990-03       Impact factor: 17.367

Review 3.  A(2A) adenosine receptor: a novel therapeutic target in renal disease.

Authors:  Mark D Okusa
Journal:  Am J Physiol Renal Physiol       Date:  2002-01

4.  Enhanced protection from renal ischemia-reperfusion [correction of ischemia:reperfusion] injury with A(2A)-adenosine receptor activation and PDE 4 inhibition.

Authors:  M D Okusa; J Linden; L Huang; D L Rosin; D F Smith; G Sullivan
Journal:  Kidney Int       Date:  2001-06       Impact factor: 10.612

5.  Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney.

Authors:  M D Okusa; J Linden; T Macdonald; L Huang
Journal:  Am J Physiol       Date:  1999-09

6.  Adenosine attenuates oxidant injury in human proximal tubular cells via A(1) and A(2a) adenosine receptors.

Authors:  H T Lee; Charles W Emala
Journal:  Am J Physiol Renal Physiol       Date:  2002-05

7.  Controlled hypotension with adenosine in cerebral aneurysm surgery.

Authors:  A Sollevi; M Lagerkranser; L Irestedt; E Gordon; C Lindquist
Journal:  Anesthesiology       Date:  1984-10       Impact factor: 7.892

8.  Pharmacological analysis of vasodilation induced by extracellular adenosine 3',5'-cyclic monophosphate in the isolated and perfused canine coronary artery.

Authors:  T Nakane; S Chiba
Journal:  J Pharmacol Exp Ther       Date:  1993-03       Impact factor: 4.030

9.  Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A(1) and A(3) receptors.

Authors:  H T Lee; C W Emala
Journal:  Am J Physiol Renal Physiol       Date:  2000-03

10.  Adenosine-angiotensin II interactions. Part II. The role of adenosine in regulating angiotensin II-induced changes in heart rate and aldosterone release.

Authors:  B J Holycross; P Li; E K Jackson
Journal:  J Pharmacol Exp Ther       Date:  1989-08       Impact factor: 4.030

View more
  3 in total

1.  2',3'-cGMP exists in vivo and comprises a 2',3'-cGMP-guanosine pathway.

Authors:  Edwin K Jackson; Zaichuan Mi; Keri Janesko-Feldman; Travis C Jackson; Patrick M Kochanek
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-02-21       Impact factor: 3.619

2.  A facile and sensitive method for quantification of cyclic nucleotide monophosphates in mammalian organs: basal levels of eight cNMPs and identification of 2',3'-cIMP.

Authors:  Xin Jia; Benjamin M Fontaine; Fred Strobel; Emily E Weinert
Journal:  Biomolecules       Date:  2014-12-12

3.  A novel adenosine precursor 2',3'-cyclic adenosine monophosphate inhibits formation of post-surgical adhesions.

Authors:  Mervyn B Forman; Delbert G Gillespie; Dongmei Cheng; Edwin K Jackson
Journal:  Dig Dis Sci       Date:  2014-04-08       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.